Description: BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Home Page: www.bioarctic.se
Warfvinges vag 35
Stockholm,
112 51
Sweden
Phone:
46 86 95 69 30
Officers
| Name | Title |
|---|---|
| Dr. Gunilla Osswald Ph.D. | President & CEO |
| Dr. Pär Gellerfors | Co-Founder, Senior VP of Business Strategy & Director |
| Prof. Lars Lannfelt | Co-Founder, Senior VP of Medical science & Director |
| Mr. Anders Martin-Lof M.B.A., M.Sc. | Chief Financial Officer |
| Ms. Johanna Fälting | Chief Research Officer & Head of Research |
| Mr. Christer Möller | VP of Pre-Clinical Development & Chief Scientific Officer |
| Mr. Oskar Bosson | VP and Head of IR & Communication |
| Mr. Leif Gallo LL.M. | General Counsel and Head of Legal & IP |
| Mr. Harald Borgeke | Head of Public Affairs |
| Ms. Frida Lekander | Head of Marketing |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 43.6681 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 17.6152 |
| Price-to-Sales TTM: | 4.7763 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 96 |